Clinical trial
Efficacy and Safety of Edaravone Dexborneol Sublingual Tablet for Post-stroke Cognitive Impairment in Patients With Acute Ischemic Stroke: a Multicenter, Randomized, Double-blind, Placebo-controlled, Exploratory Phase II Clinical Trial.
NCT06315231 is registered in ClinicalTrials.gov with Simcere Pharmaceutical Co., Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy and Safety of Edaravone Dexborneol Sublingual Tablet for Post-stroke Cognitive Impairment in Patients With Acute Ischemic Stroke: a Multicenter, Randomized, Double-blind, Placebo-controlled, Exploratory Phase II Clinical Trial.
- Lead sponsor
- Simcere Pharmaceutical Co., Ltd
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- April 8, 2024
- Completion date
- December 30, 2026
- Enrollment
- 226 (estimated)
- Sites
- 21
Conditions
As the registry lists them; a condition with its own page is linked.
post-stroke cognitive impairment